Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension

References

• European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd ed. Savona: Editrice DOGMA S.r.l.; 2003
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943–53
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56
   PubMed Web of Science ®Google Scholar
• Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971–6
   PubMed Web of Science ®Google Scholar
• Workgroup on Evidence-Based Treatment Recommendations for Glaucoma. Evidence-based management of glaucoma: recommendations of an expert panel. In: Glaucoma disease management guide, PDR 2004 1st ed. Montvale (NJ): Thomson PDR; 2003. p. 212–3
   Google Scholar
• Michaud JE, Friren B; International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132: 235–43
   Google Scholar
• Tsukamoto H, Noma H, Matsuyama S, et al. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a betablocker in patients with glaucoma. J Ocul Pharmacol Ther 2005;21:170–3
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Noma H, Mukai S, et al. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther 2005;21:395–9
   PubMed Web of Science ®Google Scholar
• Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma 2001;10:220–6
   PubMed Web of Science ®Google Scholar
• Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol. Ophthalmology 2003;110:615–24
   Google Scholar
• Simmons AT, Earl ML; Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers. Ophthalmology 2002;109:307–15
   Google Scholar
• Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603–8
   PubMed Web of Science ®Google Scholar
• Netland PA, Mroz M, Rosner SA, et al. Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2003;20:20–30
   PubMed Web of Science ®Google Scholar
• Zabriskie N, Netland PA; Brimonidine with Latanoprost Study Groups 1 and 2. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther 2003;20: 92–100
   Google Scholar
• Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002;120:915–22
   PubMed Web of Science ®Google Scholar
• Simmons ST; Alphagan/Trusopt Study Group. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001;23: 604–19
   Google Scholar
• Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies [Brinzolamide Comfort Study Group]. Surv Ophthalmol 2000;44\(Suppl 2):S141–S145
   Google Scholar
• Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0. 15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2004;88:953–6
   Google Scholar
• The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0. 005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther 2007;24: 302–9
   Google Scholar
• Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin 2005;21: 503–8
   Google Scholar
• Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma 2007;16:352–7
   PubMed Web of Science ®Google Scholar
• Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 2007;114:1248–54
   Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119–26
   PubMed Web of Science ®Google Scholar
• Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag 2006;2:337–46
   PubMedGoogle Scholar